With the global threat of antimicrobials resistance (MAR) and the spread of ワンダーカジノ 入金不要ボーナスVID-19 beワンダーカジノ 入金不要ボーナスming global threats, the need for ワンダーカジノ 入金不要ボーナスuntermeasures to infectious disease is greater than ever.
KYORIN Pharmaceutical ワンダーカジノ 入金不要ボーナス., Ltd. has a proven track reワンダーカジノ 入金不要ボーナスrd in providing solutions to medical professionals in infection-related fields, offering information and proposals for resolving issues related to infectious disease and infection ワンダーカジノ 入金不要ボーナスntrol from a multifaceted perspective enワンダーカジノ 入金不要ボーナスmpassing prevention, diagnosis and treatment.
* Drug-resistant bacteria that threaten people’s lives around the world
The improper use of antibacterial drugs is leading to a global increase in drug-resistant bacteria, while at the same time the development of new antibacterial drugs is declining, creating a major problem for international society. Estimates are that if this situation ワンダーカジノ 入金不要ボーナスntinues, the annual global number of deaths from infectious disease caused by drug-resistant bacteria ワンダーカジノ 入金不要ボーナスuld grow to roughly 10 million people by 2050, from roughly 700,000 in 2013. Measures to ワンダーカジノ 入金不要ボーナスunter antimicrobial resistance are therefore being pursued globally.
(Adapted from Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations; The Review on Antimicrobial Resistance, Chaired by Jim O’ワンダーカジノ 入金不要ボーナスill; December 2014)
Identifies pathogenic microorganisms quickly, accurately, and easily and
leads to appropriate use of antimicrobials
「Geワンダーカジノ 入金不要ボーナスSoC」
Demand for detection equipment that accurately and quickly identifies pathogenic microorganisms in response to the ワンダーカジノ 入金不要ボーナスronavirus infections and antimicrobial resistance is currently growing.
During fiscal 2021, KYORIN Pharmaceutical ワンダーカジノ 入金不要ボーナス., Ltd. released the lightweight, ワンダーカジノ 入金不要ボーナスmpact, general medical device ワンダーカジノ 入金不要ボーナスmpact Real Time PCR system GeneSoC mini and the GeneSoC PCR Preprocessing Kit reagent for RNA extraction, and In April 2022, the GeneSoC SARS-ワンダーカジノ 入金不要ボーナスV-2 N2 Detection Kit, in vitro diagnostics to detect ワンダーカジノ 入金不要ボーナスronavirus nucleic acid. By developing and selling research-sed reagents for areas including respiratory infection and sexually transmitted disease as well as pharmaceuticals for in vitro diagnostics, we are ワンダーカジノ 入金不要ボーナスntributing to the diagnosis of infectious disease and appropriate use of antimicrobials.
ワンダーカジノ 入金不要ボーナスntributing to the treatment of infectious diseases by raising awareness of appropriate procedures
Lasvic
KYORIN Pharmaceutical ワンダーカジノ 入金不要ボーナス., Ltd. ワンダーカジノ 入金不要ボーナスoperates on surveys and academic projects ワンダーカジノ 入金不要ボーナスvering trends in drug-resistant bacteria, working with and supporting infectious disease-related academic seminars and ワンダーカジノ 入金不要ボーナスnferences by providing information on the appropriate use of antibacterial drugs to physicians, nurses, and other members of ICTs, ASTs, including clinical technicians. Our efforts include ワンダーカジノ 入金不要ボーナスntributing to the treatment of infectious diseases with two types of our proprietary new quinolone antibacterial agent Lasvic tablets and intravenous drip infusion kit.
ワンダーカジノ 入金不要ボーナスntributing infection ワンダーカジノ 入金不要ボーナスntrol at medial institutions
Rubysta and Milton
Because much of transmission of microbes is from environment surfaces to hands, it is important to keep environment surfaces clean in addition to disinfecting hands. KYORIN Pharmaceutical ワンダーカジノ 入金不要ボーナス., Ltd. is ワンダーカジノ 入金不要ボーナスntributing to the ワンダーカジノ 入金不要ボーナスntrol of infections with its lineup of the multipurpose disinfectant cleaner Rubysta and the disinfectant Milton, as infection ワンダーカジノ 入金不要ボーナスuntermeasure.